Rimsys Regulatory Management Software’s Post

After some lovely feedback about my industry insights at the MedTech Forum, I am pleased so share some of the latest Investment, Innovation and Industry Insights from within MedTech. Significant acquisitions & investment this week - links to all articles in the comments. Join us tomorrow for our Inside MedTech Live with Asha Parekh from Front Line Medical Technologies! #medtech #insidemedtech #medtechnews #medtechinsights

🔍 Medtech at a Turning Point 🔍 TVM Capital Life Science’s Managing Partner, Dr. Luc Marengere, recently shared insights with Shani Alexander of BioWorld MedTech at LSI Europe '24 on the state of the medtech sector—medtech is indeed at a pivotal moment. 💬 "The entire ecosystem is coming together. It’s not just about technologies; you need investors and buyers creating a healthier, more viable industry. Now, we’re seeing companies valued at biotech levels and exciting opportunities for investment," says Luc. With over $900M under management, TVM is proud to support companies transforming patient care and medtech innovation. Notable investments, such as TVM’s support of Access Vascular, Inc. CSA Medical Inc, Kent Imaging and Vektor Medical, Inc. Medical reflect our commitment to fostering solutions that deliver tangible patient outcomes and redefine treatment pathways. As Luc notes, these are "truly transformational opportunities"—and the future is bright for medtech. Read the full article here (pay wall): https://lnkd.in/eWMrydRb #MedTech #HealthcareInnovation #VentureCapital #LifeSciences #MedTechDeals #InvestmentOpportunities

If you're at #SCOPEsummit tomorrow and attending the Clinical Trial Tech: Venture, Innovation & Partnering Conference, come hear Mayo Clinic's Manu Nair speak on a panel about trends and needs in future investment at 9:40 a.m. EST. #MayoClinic #Finance #Investment

Is your laboratory ready to scale new heights in market access and profitability? Explore how Atalan leverages advanced technology and an expansive network to turn your lab's capabilities into successful, revenue-generating ventures. Visit atalan.com to explore how our tech-enabled clinical partnership platform can broaden your market reach and drive success. #LabInnovation #MarketAccess #TransformYourLab #LaboratoryMedicine

AcuityMD Secures $45M Series B To Advance MedTech Platform Learn more & get our take 👇 https://lnkd.in/dCCxBUvh “AcuityMD’s innovative platform is reminiscent of other transformative, vertical-specific platforms that we have supported. We believe that there are also exciting opportunities to extend into other product areas and expand the value proposition, and ultimately for MedTech companies to use AcuityMD as their complete commercial operating system.” —Tengbo Li, Partner at ICONIQ Capital “I’m acutely aware of the unique challenges MedTech companies face when bringing products to market. AcuityMD has built an industry-specific platform that alleviates common pain points to help bring new treatments to patients faster. I am thrilled to be partnering with AcuityMD as it enters its next phase of growth.” — William A. Hawkins, former CEO at Medtronic “With this additional capital, we aim to launch three new products to general availability, expand our pipeline management solution to more customers, and grow our engineering and product teams by 70% by the end of 2024 to support our mission of accelerating the adoption of cutting-edge medical technology.” — Michael Monovoukas, CEO and co-founder at AcuityMD #funding #medtech #SoHCNews

Check out the latest piece by LSI’s Henry Peck, where he delves into the thought process behind medtech and healthtech industry investors who sometimes must prioritize between the quality of a founding team and the size of the market potential. Within the article, our own Kevin Chu, a Principal on our team focused on healthcare investments within the therapeutics, medical devices, and life science sectors, provided his industry insights. Kevin shares his own philosophy when it comes to venture investing, emphasizing that while sheer market potential is important, maximizing clinical benefit is the most critical, even if that means prioritizing a narrower indication, and that, more often than not, high quality teams are most adept at quickly finding this balance. See the link in comments to learn more. #healthcare #medtech #healthtech #venturecapital

#Medtech 𝐕𝐂 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐢𝐧 𝐐1 2024: 𝐅𝐨𝐜𝐮𝐬 𝐨𝐧 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐎𝐯𝐞𝐫 𝐐𝐮𝐚𝐧𝐭𝐢𝐭𝐲: Total deal value hit $3.3 billion, the highest since Q4 2022, despite historically low deal counts. 𝐌𝐚𝐣𝐨𝐫 𝐃𝐞𝐚𝐥𝐬: Freenome led with a $254M round, supported by Roche Venture Fund and Bain Capital Life Sciences. Notable smaller deals included Impulse Dynamics, Mainstay Medical, Alamar Biosciences, and Medical Microinstruments. 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲: Gilde Healthcare and Arboretum Ventures led with three deals each, while Khosla Ventures was among several investors with two investments. 𝐂𝐚𝐭𝐞𝐠𝐨𝐫𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: #Cardiovascular: Over $1.5 billion invested, with Impulse Dynamics' $136M Series E standing out. #Cancer Diagnostics: $395.3 million #Neurostimulation: $242.8 million #PersonalizedCare & #RemoteMonitoring: $226.5 million 𝐕𝐂 𝐄𝐱𝐢𝐭𝐬: Few exits noted, with exceptions like Attune Medical's $160M acquisition by Haemonetics. 𝐈𝐏𝐎 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲: Sparse, with Autonomix raising $11.1 million in its public listing. 𝐏𝐄 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲: Declined with five PE growth deals and 14 buyouts. Interest noted in Healthium Medtech and Baxter’s Vantive kidney care unit. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐮𝐭𝐥𝐨𝐨𝐤: Despite a strong start, cautious optimism prevails due to lower deal values compared to 2021 highs and uncertain interest rate expectations. Read more at the link below PitchBook #Medtech #VCFunding #InvestmentTrends #HealthcareInnovation #MedicalDevices

A key partnership between ventureLAB and Sterling Industries leads to a new memorandum of understanding (MOU) to strengthen the local MedTech community, and support the development of tomorrow’s life-changing medical devices. https://lnkd.in/erXwbQkm This MOU is great news as the MedTech stream available through the HCI will continue to support new startups as they test new hardware devices for healthcare and assist them with guidance as they aim to scale-up their businesses to compete in a highly competitive market in Canada and abroad. The Hardware Catalyst Initiative (HCI) at ventureLAB – with labs in Markham and Vaughan – is an important component of the life sciences and health tech ecosystem in the region; which is home to more than 300 sector related companies. #YorkRegion #Vaughan #MOU #MedTech #YRtech #TechnologyTest #HealthTech #LifeSciences #HardwareCatalystInitiative #Hardware #HardwareDevices #HCI David Van Slingerland, Hugh Chow, Nima Khadem Mohtaram, Ph.D. Vaughan Economic Development Raphael Costa

Absolutely love diving into the complexities of funding strategies in MedTech today. It's a reminder that securing capital isn't just about the money—it's about aligning with the right partners who understand the intricacies of your device's regulatory pathway and market potential. Whether you're navigating a 510(k) or PMA, it's crucial to match your funding source with your strategic goals. In MedTech, success often comes from strategic partnerships, not just the dollars behind them.

Flinn.ai raises a €6M Seed round to revolutionize MedTech quality management through AI software. With the escalating complexity of regulatory requirements, especially the EU Medical Device Regulation (MDR), MedTech manufacturers are encountering substantially higher compliance costs, forcing many to discontinue niche products or exit less lucrative markets – threatening the availability of essential medical products and raising entry barriers for new innovations. Flinn.ai’s SaaS solution empowers MedTech manufacturers to increase the efficiency of their compliance processes tenfold by integrating AI-powered automation into data processing, evaluation, and reporting. Andrea Zitna, Partner with our Health & TechBio team, says, “Flinn is quickly becoming the go-to regulation & compliance co-pilot for leading medtech manufacturers. We have been privileged to see Markus, Bastian, and Hasib turn their vision into reality since day 1, putting customers at the heart of every stage of their product development process. This new round is a well-deserved🍒 on top!" Speedinvest is proud to continue supporting Flinn.ai in their latest round led by Cherry Ventures with participation from SquareOne Venture Capital and prominent business angels including Matthias Weber (former President at Leica Biosystems) and Michael Reitermann (former CEO of Siemens Diagnostics). Handelsblatt has more ⬇ https://lnkd.in/e3ThGg4T #MedTech #SaaS #healthtech #fundingnews #venturecapital